High Growth Tech Stocks in the US Market

The United States market has remained flat over the past week but has shown an 8.5% increase over the past year, with earnings expected to grow by 14% annually. In this context of steady growth, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability in capturing emerging opportunities within this dynamic sector.

Advertisement

Top 10 High Growth Tech Companies In The United States

NameRevenue GrowthEarnings GrowthGrowth RatingSuper Micro Computer20.44%29.79%★★★★★★TG Therapeutics26.18%37.61%★★★★★★Alkami Technology20.02%85.16%★★★★★★Travere Therapeutics28.43%65.01%★★★★★★AVITA Medical27.91%55.77%★★★★★★TKO Group Holdings22.48%25.17%★★★★★★Clene60.86%63.07%★★★★★★Alnylam Pharmaceuticals22.76%58.40%★★★★★★Lumentum Holdings21.55%119.67%★★★★★★Ascendis Pharma32.36%59.79%★★★★★★

Click here to see the full list of 235 stocks from our US High Growth Tech and AI Stocks screener.

Let's dive into some prime choices out of from the screener.

Gilead Sciences (NasdaqGS:GILD)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Gilead Sciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for unmet medical needs globally with a market cap of $134.36 billion.

Operations: Gilead generates revenue primarily from the discovery, development, and commercialization of innovative medicines, amounting to $28.75 billion. The company operates in the United States, Europe, and internationally.

Gilead Sciences has demonstrated resilience and innovation, particularly in its HIV treatment and prevention segments. With a recent executive change, appointing Diane E. Wilfong as interim Corporate Controller, the company remains stable in leadership transitions. At the Conference on Retroviruses and Opportunistic Infections (CROI 2025), Gilead presented promising data from its ALLIANCE trial showing Biktarvy's efficacy in HIV/HBV co-infection with high virologic suppression rates of 95.4% for HIV-1. Additionally, lenacapavir continues to show potential as a long-acting PrEP solution with ongoing Phase 1 studies indicating effective plasma concentrations for over a year post-administration, reinforcing Gilead's commitment to addressing global health challenges through groundbreaking R&D efforts focused on multi-stage mechanisms of action in antiviral treatments.

NasdaqGS:GILD Earnings and Revenue Growth as at Mar 2025
NasdaqGS:GILD Earnings and Revenue Growth as at Mar 2025

nCino (NasdaqGS:NCNO)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: nCino, Inc. is a software-as-a-service company that offers cloud-based software applications to financial institutions worldwide, with a market capitalization of approximately $3.40 billion.

Operations: nCino generates revenue primarily from its software and programming segment, amounting to $522.98 million. The company focuses on delivering cloud-based solutions tailored for financial institutions both in the U.S. and internationally.

nCino, poised for significant growth with a projected revenue increase of 13.3% annually, outpaces the U.S. market forecast of 8.5%. This fintech firm is on track to profitability within three years, reflecting an impressive expected earnings surge of 126.78% per year. Recent strategic board enhancements and executive shifts underscore its commitment to robust governance and innovation in financial software solutions, marking nCino as a dynamic contender in the high-growth tech landscape despite current unprofitability challenges.

NasdaqGS:NCNO Revenue and Expenses Breakdown as at Mar 2025
NasdaqGS:NCNO Revenue and Expenses Breakdown as at Mar 2025

Fair Isaac (NYSE:FICO)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Fair Isaac Corporation specializes in developing software that utilizes analytics and digital decisioning technologies to help businesses automate and improve decision-making processes across various regions, with a market cap of $46.87 billion.

Operations: The company generates revenue primarily from two segments: Scores, contributing $963.21 million, and Software, contributing $812.22 million.

Fair Isaac, known for its FICO scores, is making strategic moves that underscore its adaptability and foresight in the financial technology landscape. Recently, Fair Isaac announced a significant partnership with Fujitsu to expand its offerings into Japan, aiming to enhance digital transformation in the financial sector starting July 2025. This collaboration is set to leverage Fujitsu's deep market penetration and technological prowess to introduce FICO's advanced decisioning tools across various financial platforms. Additionally, Fair Isaac's recent earnings report showcased a robust performance with first-quarter revenue rising from $382.06 million to $439.97 million year-over-year and net income increasing significantly from $121.07 million to $152.53 million. These figures not only reflect solid growth but also highlight Fair Isaac’s capacity for maintaining momentum in innovation and market expansion.

NYSE:FICO Revenue and Expenses Breakdown as at Mar 2025
NYSE:FICO Revenue and Expenses Breakdown as at Mar 2025

Seize The Opportunity

Searching for a Fresh Perspective?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NasdaqGS:GILD

Gilead Sciences

A biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

Solid track record established dividend payer.

Advertisement

Weekly Picks

VA
valuebull
GOAI logo
valuebull on Eva Live ·

Is this the AI replacing marketing professionals?

Fair Value:US$7.4342.5% undervalued
30 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
ZA
PME logo
ZayaanS on Pro Medicus ·

Pro Medicus: The Market Is Confusing a Lumpy Quarter With a Broken Business

Fair Value:AU$196.7833.2% undervalued
31 users have followed this narrative
6 users have commented on this narrative
18 users have liked this narrative
ST
WBD logo
SteveGruber on Warner Bros. Discovery ·

The Rising Deal Risk That Helped Sink Netflix’s $72 Billion Bid for Warner Bros. Discovery  

Fair Value:US$18.1752.7% overvalued
5 users have followed this narrative
1 users have commented on this narrative
3 users have liked this narrative
PD
VRT logo
pdixit1 on Vertiv Holdings Co ·

The Infrastructure AI Cannot Be Built Without

Fair Value:US$408.6435.3% undervalued
35 users have followed this narrative
3 users have commented on this narrative
17 users have liked this narrative

Updated Narratives

OO
MU logo
OOO97 on Micron Technology ·

Position to be managed in the supercycle of memory but too expensive for long-term hold

Fair Value:US$124.236.7% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
OO
QXO logo
OOO97 on QXO ·

QXO aims for $24B revenue by 2031 with AI-driven margin expansion (Priced for good execution)

Fair Value:US$32.8734.0% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AN
DXN logo
Anthony_Lee on DXN Holdings Bhd ·

Investing in Resilience: The Case for DXN Holdings Berhad in 2026

Fair Value:RM 0.6121.3% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

KA
NU logo
kabz2342 on Nu Holdings ·

Nu holdings will continue to disrupt the South American banking market

Fair Value:US$64.377.2% undervalued
51 users have followed this narrative
3 users have commented on this narrative
27 users have liked this narrative
AN
AnalystConsensusTarget
MSFT logo
AnalystConsensusTarget on Microsoft ·

Analyst Commentary Highlights Microsoft AI Momentum and Upward Valuation Amid Growth and Competitive Risks

Fair Value:US$59631.3% undervalued
1302 users have followed this narrative
2 users have commented on this narrative
10 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$253.0227.8% undervalued
1102 users have followed this narrative
7 users have commented on this narrative
34 users have liked this narrative